LEADER 7: cardiovascular risk profiles of US and European participants in the LEADER diabetes trial differ

Public Deposited
Analytics

Downloadable Content

Download PDF
Request Version for Screen Reader
Creator
  • Rutten, Guy E H M
    • Other Affiliation: Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, STR 6.131, P.O. Box 85500, 3508, GA, Utrecht, The Netherlands
  • Tack, Cees J
    • Other Affiliation: Department of Internal Medicine, Radboud University Medical Center, Nijmegen, The Netherlands
  • Pieber, Thomas R
    • Other Affiliation: Division of Endocrinology and Metabolism, Medical University of Graz, Graz, Austria
  • Comlekci, Abdurrahman
    • Other Affiliation: Division of Endocrinology, Dokuz Eylul University Medical School, Inciralti, Izmir, Turkey
  • Ørsted, David D
    • Other Affiliation: Novo Nordisk, Søborg, Denmark
  • Baeres, Florian M M
    • Other Affiliation: Novo Nordisk, Søborg, Denmark
  • Marso, Steven P
    • Other Affiliation: Department of Internal Medicine, UT Southwestern, Dallas, TX, USA
  • Buse, John
    • Affiliation: School of Medicine, Department of Medicine
Abstract
  • Abstract Aims To determine whether US and European participants in the Liraglutide Effect and Action in Diabetes: Evaluation of cardiovascular outcome Results (LEADER) trial differ regarding risk factors for cardiovascular mortality and morbidity. Methods Baseline data, stratified for prior cardiovascular disease (CVD), were compared using multivariable logistic regression analysis to establish whether region is an independent determinant of achieved targets for glycated hemoglobin (HbA1c), blood pressure (BP), and low-density lipoprotein (LDL)-cholesterol. Results Independent of CVD history, US participants were more often of non-White origin and had a longer history of type 2 diabetes, higher body weight, and higher baseline HbA1c. They had substantially lower systolic and diastolic BP, and a marginally lower LDL-cholesterol level. Fewer US participants were diagnosed with left ventricular dysfunction. In the largest group of patients, those with prior CVD and the highest cardiovascular risk, US participants were more often female, had a higher waist circumference, and had a decreased estimated glomerular filtration rate, but less frequently prior myocardial infarction or angina pectoris. Conclusions There were baseline differences between US and European participants. These differences may result from variation in regional targets for cardiovascular risk factor management, and should be considered in the analysis and reporting of the trial results. Clinical trial identifier: ClinicalTrials.gov, NCT01179048
Date of publication
DOI
Identifier
Resource type
  • Article
Rights statement
  • In Copyright
Rights holder
  • The Author(s)
Language
  • English
Bibliographic citation
  • Diabetology & Metabolic Syndrome. 2016 Jun 02;8(1):37
Publisher
  • BioMed Central

Relations

Parents:

This work has no parents.

Items

Thumbnail Title Date Uploaded Visibility Actions
file details 13098_2016_article_153.pdf 2019-05-06 Public Download